ADAP
Price
$0.32
Change
+$0.01 (+3.23%)
Updated
Apr 3 closing price
Capitalization
84.53M
41 days until earnings call
ORMP
Price
$2.16
Change
-$0.04 (-1.82%)
Updated
Apr 3 closing price
Capitalization
87.83M
54 days until earnings call
Ad is loading...

ADAP vs ORMP

Header iconADAP vs ORMP Comparison
Open Charts ADAP vs ORMPBanner chart's image
Adaptimmune Therapeutics
Price$0.32
Change+$0.01 (+3.23%)
Volume$3.94M
Capitalization84.53M
Oramed Pharmaceuticals
Price$2.16
Change-$0.04 (-1.82%)
Volume$154.79K
Capitalization87.83M
ADAP vs ORMP Comparison Chart
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. ORMP commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and ORMP is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ADAP: $0.32 vs. ORMP: $2.16)
Brand notoriety: ADAP and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 211% vs. ORMP: 53%
Market capitalization -- ADAP: $84.53M vs. ORMP: $87.83M
ADAP [@Biotechnology] is valued at $84.53M. ORMP’s [@Biotechnology] market capitalization is $87.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 3 bullish TA indicator(s).

  • ADAP’s TA Score: 4 bullish, 4 bearish.
  • ORMP’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than ORMP.

Price Growth

ADAP (@Biotechnology) experienced а +47.23% price change this week, while ORMP (@Biotechnology) price change was -6.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

ADAP is expected to report earnings on May 15, 2025.

ORMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($87.8M) and ADAP($84.5M) have the same market capitalization . ORMP YTD gains are higher at: -10.744 vs. ADAP (-39.874). ORMP has higher annual earnings (EBITDA): 9.44M vs. ADAP (-55.9M). ADAP has more cash in the bank: 186M vs. ORMP (142M). ORMP has less debt than ADAP: ORMP (429K) vs ADAP (74.5M). ADAP has higher revenues than ORMP: ADAP (175M) vs ORMP (0).
ADAPORMPADAP / ORMP
Capitalization84.5M87.8M96%
EBITDA-55.9M9.44M-592%
Gain YTD-39.874-10.744371%
P/E RatioN/A20.91-
Revenue175M0-
Total Cash186M142M131%
Total Debt74.5M429K17,366%
FUNDAMENTALS RATINGS
ADAP vs ORMP: Fundamental Ratings
ADAP
ORMP
OUTLOOK RATING
1..100
5583
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9785
PRICE GROWTH RATING
1..100
9761
P/E GROWTH RATING
1..100
10045
SEASONALITY SCORE
1..100
n/a36

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (61) in the Biotechnology industry is in the same range as ORMP (68) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as ADAP (97) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ADAP’s over the last 12 months.

ORMP's Price Growth Rating (61) in the Pharmaceuticals Other industry is somewhat better than the same rating for ADAP (97) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than ADAP’s over the last 12 months.

ORMP's P/E Growth Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for ADAP (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 28 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PHRRF0.14N/A
+3.57%
PharmaTher Holdings Ltd.
TYCMY33.150.82
+2.53%
Tingyi Cayman Islands Holdings Corp.
DSNKY24.440.20
+0.83%
Daiichi Sankyo Co., Ltd.
FRFHF1470.26-21.74
-1.46%
Fairfax Financial Holdings Ltd.
BRCHF0.13-0.01
-7.14%
Brainchip Holdings Ltd.